Alkermes plc (ALKS) vs Caris Life Sciences, Inc. (CAI)
A side-by-side comparison of Alkermes plc and Caris Life Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALKS
Alkermes plc
$42.76HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CAI
Caris Life Sciences, Inc.
$30.39HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ALKS vs CAI
growth of $100 · dividends reinvested · last 1yALKS +38.9% (+38.9%/yr)CAI +8.5% (+8.5%/yr)ALKS compounded faster over this window
ALKS CAI
ALKS vs CAI: by the numbers
- •CAI is the larger company ($8.59B vs $7.17B market cap).
- •CAI trades at the lower trailing earnings multiple (84.91 vs 111.64 P/E), one valuation lens rather than an overall verdict.
- •CAI converts more revenue to profit (10.62% vs 3.97% net margin).
- •CAI grew revenue faster over the past five years (26.15% vs 8.68% CAGR).
Metrics side by side
Valuation
| Metric | ALKS | CAI |
|---|---|---|
| P/E ratio | 111.64 | 84.91 |
| Forward P/E | N/A | 261.92 |
| P/S ratio | 4.30 | 8.68 |
| P/B ratio | 3.97 | 14.52 |
| EV / EBITDA | 46.03 | 47.99 |
| FCF yield | 3.09% | 1.71% |
Profitability
| Metric | ALKS | CAI |
|---|---|---|
| Gross margin | 84.56% | 69.66% |
| Operating margin | 17.21% | 5.56% |
| Net margin | 3.97% | 10.62% |
| ROE | 3.66% | 17.77% |
| ROIC | 2.12% | 14.76% |
Growth (annualized)
| Metric | ALKS | CAI |
|---|---|---|
| Revenue CAGR (5Y) | 8.68% | 26.15% |
| FCF CAGR (5Y) | 20.00% | N/A |
| Total return CAGR (5Y) | 6.73% | N/A |
Frequently asked
- Which has the lower trailing P/E, ALKS or CAI?
- CAI has the lower trailing P/E: ALKS trades at 111.64 and CAI at 84.91. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, ALKS or CAI?
- Over the past five years, CAI grew revenue faster — ALKS at a 8.68% CAGR versus CAI at 26.15%.
- Is ALKS or CAI more profitable?
- CAI runs the higher net margin — ALKS at 3.97% versus CAI at 10.62%.
Go deeper
Dig into the metrics
Alkermes P/E ratioCaris Life Sciences P/E ratioAlkermes ROECaris Life Sciences ROEAlkermes operating marginCaris Life Sciences operating marginAlkermes revenue growthCaris Life Sciences revenue growthAlkermes free cash flowCaris Life Sciences free cash flow
Alkermes & Caris Life Sciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.